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Abstract
Mucopolysaccharidoses (MPS) are rare genetic diseases caused by the deficiency of one of the lysosomal enzymes
involved in the glycosaminoglycan (GAG) breakdown pathway. This metabolic block leads to the accumulation of
GAG in various organs and tissues of the affected patients, resulting in a multisystemic clinical picture, sometimes in-
cluding cognitive impairment. Until the beginning of the XXI century, treatment was mainly supportive. Bone marrow
transplantation improved the natural course of the disease in some types of MPS, but the morbidity and mortality re-
stricted its use to selected cases. The identification of the genes involved, the new molecular biology tools and the
availability of animal models made it possible to develop specific enzyme replacement therapies (ERT) for these dis-
eases. At present, a great number of Brazilian medical centers from all regions of the country have experience with
ERT for MPS I, II, and VI, acquired not only through patient treatment but also in clinical trials. Taking the three types
of MPS together, over 200 patients have been treated with ERT in our country. This document summarizes the expe-
rience of the professionals involved, along with the data available in the international literature, bringing together and
harmonizing the information available on the management of these severe and progressive diseases, thus disclos-
ing new prospects for Brazilian patients affected by these conditions.
Key words: mucopolisaccharidoses, Hurler syndrome, Hunter syndrome, Maroteaux-Lamy syndrome, enzyme replacement therapy,
treatment guidelines.
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Mucopolysaccharidoses (MPS) are a group of inborn
errors of metabolism caused by a deficiency of specific
lysosomal enzymes that affect glycosaminoglycan (GAG)
catabolism. The accumulation of GAG in various organs
andtissuesofpatientsaffectedbyMPSresultsinaseriesof
signs and symptoms which make up a multisystemic clini-
calpicture.Todate,elevenenzymedefectsthatcauseseven
different types of MPS have been identified (Neufeld and
Muenzer, 2001).
The participation of a multidisciplinary team of spe-
cialized professionals is recommended for the diagnosis,
treatment, and monitoring of patients with MPS, because
these diseases are rare and exhibit multisystemic involve-
ment (Muenzer, 2004). A group of Brazilian professionals
with experience in the treatment of MPS, representing all
regions of the country, met to draft these guidelines for the
treatmentofMPSI,II,andVI,forwhichtherecurrentlyisa
specific therapy.
General Information, Clinical Picture and
Classification of MPS I, II, and VI
MPS I
Mucopolysaccharidosis type I (MPS I) is a chronic,
progressive, multisystemic lysosomal disease caused by a
deficiency or absence of activity of the -L-iduronidase
(IDUA) enzyme. Different mutations can cause variations
in IDUA enzyme activity that are associated, in part, with
the clinical variability observed over the course of the dis-
ease (Hirth et al., 2007; Pastores et al., 2007). MPS I, like
the majority of lysosomal diseases, is inherited in an auto-
somal recessive manner and has an incidence of approxi-
mately1in100,000livebirthsfortheHurlerphenotypeand
up to 1 in 800,000 live births for the Scheie phenotype
(Lowry et al., 1990; Nelson, 1997; Meikle et al., 1999;
Poorthuis et al., 1999; Neufeld and Muenzer, 2001).
The most common manifestations of MPS I include a
characteristic facies, corneal clouding, macroglossia, hear-
ing loss, hydrocephaly, cardiopathy, respiratory problems,
hepatosplenomegaly, inguinal and umbilical hernia, dysos-
tosis multiplex, limited joint mobility, and cognitive im-
pairment. In addition, the accumulation of GAGs in rigid
structures and paraspinal ligaments increases the potential
for morbidity, resulting in major risks to the cervical col-
umn (Hite et al., 2000; Weisstein et al., 2004; Fuller et al.,
2005). Due to the involvement of various organs and tis-
sues, patients with MPS I frequently require surgical inter-
ventions with a high rate of complications (Ard et al.,
2005).
MPS I is commonly classified into three clinical syn-
dromes: Hurler, Hurler-Scheie, and Scheie. Because of the
high variability of MPS I and the overlapping of symptoms
in patients, it seems more appropriate to classify patients as
having the attenuated form or the severe form (Vijay and
590 Giugliani et al.Wraith, 2005). A review of this classification is currently
under way.
Severe form (Hurler syndrome): This is the most
severe MPS I phenotype (Soliman et al., 2007), character-
ized by impaired cognitive development, progressive coar-
sening of facial features, hepatosplenomegaly, respiratory
failure, cardiac valvulopathy, recurrent otitis media, cor-
nealclouding,musculoskeletalmanifestationssuchasjoint
stiffness and contractures, and dysostosis multiplex. The
symptoms arise after birth and progress rapidly (Pastores et
al., 2007). Most of the patients with the severe phenotype
which are not submitted to a specific treatment progress to
death, on average, before the age of 10 years, due to com-
plications related to brain damage or cardiorespiratory
problems (Weisstein et al., 2004; Boelens, 2006).
Attenuated form (Hurler-Scheie syndrome): This
phenotypemanifestsininfancy,howeverwithintermediate
severity when compared with the Hurler phenotype. The
somatic symptoms reduce life expectancy to the second or
third decade of life (Pastores et al., 2007; Soliman et al.,
2007). Generally, there is no cognitive impairment, but
some patients may exhibit mild learning difficulties (Bjo-
raker et al., 2006).
Scheie syndrome: This is the most attenuated form
ofMPSI(Solimanetal.,2007),Inwhichthesymptomsoc-
cur later and progress slowly. Patients exhibit normal intel-
ligence and survive until adulthood (Pastores et al., 2007).
MPS II
Mucopolysaccharidosis II (MPS II or Hunter syn-
drome) is a rare genetic disease caused by deficiency of the
lysosomal enzyme iduronate-2-sulfatase (IDS). MPS II has
anincidenceofapproximately0.31to0.71per100,000live
births (Nelson, 1997; Nelson et al., 2003; Baenher et al.,
2005), and is found almost exclusively in young males be-
cause it is an X-linked condition. Recently, however, af-
fected females – with a clinical picture in many cases
similar to that of the young males – have been described
(Tuschl et al., 2005). MPS II is a chronic, progressive dis-
ease with a clinical picture similar in certain aspects to that
of MPS I: there is great variability in the clinical manifesta-
tions, including central nervous system involvement, and
can therefore be classified into a severe or “neuropathic”
form and an attenuated or “non-neuropathic” form (Martin
et al., 2008; Wraith et al., 2008).
Patients with MPS II exhibit upper respiratory tract
dysfunctions, which can be classified as obstructive or re-
strictive (Sanjurjo-Crespo, 2007; Wraith et al., 2008).
Thesepatientsalsoexperienceagreaterfrequencyofrecur-
rent respiratory infections (Martin et al., 2008). Another
frequent complication, which also occurs in the other MPS
types, is sleep apnea (Sanjurjo-Crespo, 2007; Martin et al.,
2008; Wraith et al., 2008). With respect to musculoskeletal
disorders, joint stiffness, pelvic dysplasia, and vertebral
and rib abnormalities may be present (Sanjurjo-Crespo,
2007). Bone manifestations are called “dysostosis multi-
plex” ad exhibit specific characteristics in various bones
(Martin et al., 2008). Gastrointestinal tract manifestations
include hepatomegaly, associated or not with splenome-
galy (Wraith et al., 2008). Umbilical and inguinal hernias
are frequent findings as well (Sanjurjo-Crespo, 2007; Mar-
tin et al., 2008; Schumacher et al., 2008). Most patients de-
velop recurrent otitis and virtually all will have some
degree of hearing loss (Martin et al., 2008). Dental abnor-
malities, as well as gingival hypertrophy and hyperplasia,
may also be found in these patients (Martin et al., 2008).
Cardiologic manifestations are common and are usually
observed at around 5 years of age, generally constituting
the primary cause of death (Martin et al., 2008). Ocular
manifestations include papilledema, optic nerve atrophy,
and retinal dystrophy (Anawis, 2006; Martin et al., 2008;
Schumacher et al., 2008). Patients with MPS II also exhibit
skin disorders, such as hirsutism (Wraith et al., 2008),
Mongolian spot, and papular lesions, caused by GAG de-
posits and considered typical of this type of MPS, although
not exclusive to it (Ochiai et al., 2003; Martin et al., 2008;
Wraith et al., 2008).
Fromaneurologicalpointofview,abouttwothirdsof
MPS II patients present with manifestations such as devel-
opmentaldelayand/orneurologicalregression(Schwartzet
al., 2007). These findings indicate the presence of the
“neuropathic” form of the disease. More severely affected
patients may experience seizures (Martin et al., 2008),
which sometimes manifest at the onset of the neuro-
degenerative picture. Behavioral changes, such as hyperac-
tivity, aggressiveness, and obstinacy, may also be present
in severely affected patients (Martin et al., 2008). The at-
tenuated(“non-neuropathic”)formischaracterizedbylittle
or no central nervous system involvement, with preserved
intelligence and an extended life expectancy. At times,
classificationisdifficult,becausetherearepatientswithin-
termediatecharacteristics,suchasearlyonsetofrespiratory
problems, progressive upper airway obstruction, and com-
pression of the vertebral column, among other signs and
symptoms (Frossairt et al., 2007; Sanjurjo-Crespo, 2007).
Communicating hydrocephalus and spinal cord compres-
sionsyndrome,aswellascarpaltunnelsyndrome,mayalso
occur (Martin et al., 2008).
MPS VI
Mucopolysaccharidosis VI (MPS VI or Maroteaux-
Lamy syndrome) is a rare autosomal recessive genetic dis-
ease caused by deficiency of the enzyme N-acetylgalacto-
samine-4-sulfatase or arylsulfatase B (ARSB). The
estimated incidence of MPS VI is 0.23 per 100,000 live
births (Baenher et al., 2005), but in Brazil preliminary data
Guidelines for the treatment of MPS 591indicate that this incidence is higher (Coelho et al., 1997;
Albano et al., 2000).
Patients with MPS VI exhibit a wide variability of
multisystemic symptoms with a chronic and progressive
course, where primarily the skeletal and cardiopulmonary
systems,cornea,skin,liver,spleen,brain,andmeningesare
affected. The somatic involvement can resemble that of in-
dividuals with MPS I, but the patients’ intelligence is usu-
ally normal. In general, patients have a short trunk and a
thoracolumbar gibbus. Ocular manifestations include cor-
neal clouding, glaucoma, pseudoglaucoma, and papille-
dema with optic atrophy in more advanced stages.
Hypoacusia is the most common otological manifestation,
generally associated with a conductive and neurosensory
component. Respiratory involvement results from extrinsic
and intrinsic alterations to the airways. A short neck, ele-
vated epiglottis, deep cervical fossa, hypoplastic mandible,
and tracheobronchomalacia contribute to the respiratory
problems. Obstructive sleep apnea is also a frequent com-
plication in MPS VI.
Although patients with MPS VI do not exhibit mental
retardationasadirectconsequenceofthedisease,theircog-
nitive acquisitions may be impaired by the auditory and vi-
sual deficits and by the physical limitations inherent to the
disease. Physical growth and development may be normal
in the first years of life, stagnating at around six or eight
yearsofage(Giuglianietal.,2007).Cardiacinvolvementis
a significant component of this disease and is responsible
foralargepartofthepatients’morbidityandmortality(Tan
etal.,1992;Dilberetal.,2002;Azevedoetal.,2004;Oudit
et al., 2007a,b). Most of the individuals with MPS VI prog-
ress to death in their 2
nd or 3
rd decade of life, with heart fail-
ure, often secondary to chronic respiratory obstruction, as
the primary cause (Harmatz et al., 2004).
Biochemical and Genetic Aspects
Laboratory diagnosis
A clinical suspicion of MPS constitutes grounds for
performing a urinary GAG concentration determination.
These concentrations are elevated in virtually all types of
MPS, but the occurrence of normal levels is not reason
enough to rule out this diagnosis in a patient with a sugges-
tive clinical picture. Measurement of urinary GAG concen-
trations can be done by various methods. One recom-
mended test is quantification by reaction with DMB
(dimethylmethylene blue) solution. In contact with GAGs,
DMBproducesacompoundwhoseabsorbancecanbemea-
sured at 520 nm, and the reaction is linear up to 70 g/dL
(De Jong et al., 1989). The results can be expressed as mg
GAGs/mgcreatinine.Eventhoughonly250Lofurineare
required for the reaction, a minimum of 2 mL should be
senttothelaboratory(maybe24-hurineorasinglerandom
urine specimen). The urine should be kept frozen until the
GAG concentration determination is performed. GAG lev-
elsinindividualswithMPSareusuallyveryelevated(three
or more times) compared to normal levels. Urinary GAG
excretion in normal individuals is higher at birth, decreas-
ing rapidly thereafter (Iwata et al., 2000); after the age of
21 years the concentration no longer changes. Therefore,
the results must be interpreted according to the reference
standards for each age bracket.
Chromatography or electrophoresis can be used to
identify which type of GAG is present in excess (e.g.,
dermatan sulfate, heparan sulfate, keratan sulfate), which
helps define which enzymes should be tested initially
(Leistner and Giugliani, 1998). A diagnosis of MPS should
be confirmed via enzyme assay, documenting the deficient
enzyme activity that is specific to each type of MPS. Any
diagnostic test should be reviewed by a professional with
experienceinlysosomaldiseases,sincetheassaysarecom-
plexandtheresultsareoftendifficulttointerpret(Muenzer,
2004).
Identification of the genotype can be important for
predictingthephenotype(andinsomecasesfortherapeutic
decisions), for allowing genetic family counseling, and for
aiding in prenatal diagnosis. Therefore, it is necessary to
obtain the DNA of the patient and/or a family member,
which is generally extracted from blood, but may alterna-
tively be obtained from oral mucosa cells, saliva, or other
materials.
Genetic aspects
MPS I
To date, approximately 100 mutations have been
identified in the IDUA gene (Vijay and Wraith, 2005).
Among these, W402X and Q70X have been associated
with the severe form of the disease, the Hurler Syndrome
(Fulleretal.,2005).Describedasnullalleles,bothareasso-
ciated with undetectable production of the IDUA protein
(Matte et al., 2003). Besides these, two other less common
mutations (R89Q and R89W) have been found in patients
with the attenuated phenotype (Hein et al., 2003). The rela-
tive frequency of the mutations considered to be prevalent
seems to have a different pattern in Brazilian patients, pos-
sibly due to the greater miscegenation of our population,
with implications for the molecular analysis protocols to be
usedinourcountry(Matteetal.,2000;Pereiraetal.,2008).
Although molecular tests may determine the geno-
type, clinical and laboratory tests, which are useful for con-
firming the diagnosis, are not able to detect small
differences in residual enzyme activity, thus making it im-
possible to predict the severity of the disease (Pastores et
al., 2007). Therefore, factors such as the age at onset of
symptoms and the presence of two null mutations and of
specific clinical characteristics (such as gibbus formation
592 Giugliani et al.and delayed development) are important for a more precise
classification of the disease (Pastores et al., 2007).
MPS II
MPS II is the only mucopolysaccharidosis with
X-linked inheritance. The IDS gene is located at Xp28.1
and more than 300 mutations (including deletions, inser-
tions, and substitutions) have been identified so far (Li et
al., 1999). However, a significant correlation between the
type of mutation and the phenotype has not yet been estab-
lished, although patients with total or partial deletion of the
gene or with rearrangements between the gene and the
pseudogene may exhibit a more severe phenotype. More-
over, it is interesting to observe that the same mutation can
be associated with different phenotypes (Martin et al.,
2008).
MPS VI
MPS VI is inherited in an autosomal recessive man-
ner. The gene that codifies the enzyme arylsulfatase B
(ARSB) is located on chromosome 5q13-14. The panel of
mutations detected so far is fairly heterogeneous (Kara-
georgos et al., 2007), with a low relative frequency of each
mutation. Only in Portugal and in Brazil have relatively
common mutations been identified (Petry et al., 2003,
2005). A correlation between urinary GAG excretion and
the clinical phenotype has now been established (Swiedler
et al., 2005), but there is no well-established correlation yet
with the genotype of the affected individuals (Litjens et al.,
1996).
Genetic Counseling and Prenatal Diagnosis
As genetic counseling provides the family with infor-
mation regarding reproductive risks, it can contribute to-
ward preventing the recurrence of MPS I, II, and VI. The
risk of recurrence for a normal couple with a child affected
by MPS I or VI, which are inherited in an autosomal reces-
sive mode, is 25% for each new pregnancy. As in most
autosomal recessive disorders, parental consanguinity is
often present (Neufeld and Muenzer, 2001). In the case of
MPSII,anX-linkedcondition,identificationoffemalecar-
riers is very important since, for each pregnancy, a female
carrier has a 25% risk of having an affected child (50% risk
for a male child). In families with a prior history of one of
these types of MPS, prenatal diagnosis by means of chori-
onic villus biopsy or amniotic fluid collection during the
first or second trimester of pregnancy, respectively, can de-
tect further cases. The level of enzyme activity in the cells
(by direct study or after culturing) leads to the diagnosis.
Enzymatic diagnosis can be performed in umbilical cord
blood, but the risks of the procedure and the gestational age
at diagnosis are increased in this case. When mutations are
already known in the family, this diagnosis may be quickly
obtained by molecular analysis of the material collected
(Rogoyski et al., 1985).
Treatment
Before the advent of hematopoietic stem cell trans-
plant (HSCT) and especially of enzyme replacement ther-
apy, the main focus of the treatment of MPS I, II, and VI
wasthepreventionandmanagementofcomplications.This
treatment was symptomatic and palliative, based on a
multidisciplinaryteaminwhichtheparticipationofdiverse
medical specialties, such as cardiology, pulmonology, an-
esthesiology, orthopedics, physiatrics, otorhinolaryngo-
logy, ophthalmology, neurosurgery, etc., has been very
important. This approach, aimed not only at providing
treatment but also at promoting health, has been very im-
portant, even after the development of specific treatments.
Physical therapists, occupational therapists, psychologists,
and speech therapists are also essential in maintaining the
health of these patients, preventing complications, and, to a
certain degree, delaying the progression of the disease
(Pastores et al., 2007).
In the 1980s, the treatment of MPS with HSCT was
proposed (Krivit, 2004; Lange et al., 2006), and in the
1990s Enzyme Replacement Therapy (ERT) was devel-
oped, providing two therapeutic tools for restoring, at least
partially, the activity of the deficient enzyme. ERT became
a reality approved for clinical use in 2003 for MPS I, in
2005 for MPS VI, and in 2006 for MPS II (Kakkis et al.,
2001a,b;Wraithetal.,2004,2007;Harmatzetal.,2005a,b,
2008; Wraith, 2005; Muenzer et al., 2006, 2007; Sifuentes
et al., 2007; Clarke, 2008; Clarke et al., 2009; Giugliani et
al., 2009).
Hematopoietic Stem Cell Transplantation (HSCT)
HSCT has been used in patients with mucopoly-
saccharidosis for the purpose of correcting the enzyme de-
ficiency (Boelens et al., 2007). Although it is a high-risk
procedure with a high morbidity/mortality rate, many stud-
ies reveal that HSCT can, in fact, change the natural history
of the disease, increasing life expectancy and improving
many systemic abnormalities (Vellodi et al., 1997; Wraith
et al., 2007). However, its indication still depends on the
type of MPS, the patient’s clinical picture, his/her age, and
whether or not there is neurological impairment (McKinnis
etal.,1996;Aldenhovenetal.,2008;Muenzeretal.,2009).
MPS I
The main indication of HSCT is for patients with the
severe form of MPS I, because – if performed before two
years of age – it seems to favorably and significantly alter
their cognitive impairment (Boelens et al., 2007; Muenzer
et al., 2009). Age is an important factor, since in our coun-
try many patients are diagnosed only after or close to the
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ble donor is required, which may delay the procedure con-
siderably, also reducing the potential benefits (Muenzer et
al., 2009). Another relevant aspect is the difficulty in pre-
dicting with certainty, at the onset of the disease, which pa-
tients will develop the severe form, making it hard to
identify those for whom the risk-to-benefit ratio of HSCT
wouldbefavorable(Fulleretal.,2005).Thus,despiteinter-
national experience indicating that the potential benefit of
HSCT is superior to that of ERT in patients with the severe
formofMPSIwhenperformedbeforetwoyearsofage,the
difficulties mentioned above lead to HSCT being per-
formed on a rather limited basis in Brazilian patients with
M P SI-areality that should be changed.
HSCT can halt progression of the neurological defi-
cit, prevent premature death due to heart or liver disease,
and prolong the survival of affected children. However,
evenwhenperformedearly,HSCTdoesnotcorrectskeletal
deformities, despite improving odontoid dysplasia and ac-
celerating growth. Ophthalmologic abnormalities also im-
prove significantly with HSCT. Pulmonary complications
arefrequentfollowingtransplantation,andtheiroccurrence
is related to several pre-transplant risk factors. There is evi-
dence that ERT initiated around 12 weeks prior to trans-
plant may reduce respiratory complications during the
post-transplant period, which would be an indication for its
use, although the follow-up time has not yet been long
enoughtopermitassessmentofthelong-termimpactofthis
combination (Tolar et al., 2008). Graft-versus-host disease
(GVHD) is also reported frequently, and various strategies
have been used in the attempt to reduce this complication
that greatly alters the patients’ quality of life. The results of
the transplants performed more recently show significant
progress with this procedure and a survival rate of over
70% (Staba et al., 2004; Boelens et al., 2007; Aldenhoven
etal.,2008;Prasadetal.,2008),howevertheratesobtained
in the northern hemisphere cannot be automatically ex-
tended to Brazil, due to the different local conditions.
MPS II
To date, the results of bone marrow transplants
[BMT] in patients with MPS II have not been considered
satisfactory (Martin et al., 2008; Wraith et al., 2008). How-
ever, encouraging developments have now been reported
with HSCT performed very early in a limited number of
MPSIIpatients(Martinetal.,2006;Prasadetal.,2008).In
general, this therapy has not been recommended for these
patients, due to the lack of clearly demonstrated neurologi-
cal benefits and the high rate of morbidity and mortality
(Zareba, 2007).
MPS VI
BMT is considered a therapeutic alternative for MPS
VI (Herskhovitz et al., 1999), but ever since the introduc-
tionofERTithasbeenrelegatedtoasecondplace,because
the risks of HSCT do not appear to exceed the benefits in
thistypeofMPS,oncepatientsdonothaveacognitivedef-
icit, and the systemic problems have responded satisfacto-
rily to ERT without the risks of BMT (Giugliani et al.,
2007).
Outline of the transplantation protocol
A patient with an indication for transplantation (in
general, a patient under two years of age with the severe
form of MPS I) should be referred to a BMT/HSCT refer-
ence unit capable of performing this type of procedure in
these patients. Transplant shall be indicated only after a
careful evaluation with respect to the basic disease and to
prior complications, primarily pulmonary and neurological
ones.Asuitablycompatibledonormaybefoundamongthe
members of the family or in national and international vol-
unteer donor banks. Donors with greater compatibility and
higher enzyme concentrations will be preferentially se-
lected. The patient will undergo the protocol in use in the
reference department. Following the infusion of stem cells,
all supportive care measures will be maintained until the
graft takes. During the severe pancytopenia period, broad-
spectrum antibiotics, transfusions of irradiated blood prod-
ucts, total parenteral nutrition, and water-electrolyte re-
placement will be used. One month after the infusion of
stem cells, graft acceptance will be confirmed by complete
blood count, molecular biology techniques, and enzyme
evaluation. The patient will be followed regularly at the
transplant unit by means of enzyme concentration determi-
nations, evaluation of graft acceptance, and monitoring
with respect to post-transplant complications.
Enzyme Replacement Therapy (ERT)
Enzyme replacement therapy (ERT) is a treatment
that consists of the periodic intravenous administration of
the specific enzyme that is deficient in the patient. The first
effective treatment with ERT performed in patients with
Gaucher disease (Barton et al., 1990) led to the search for a
similar treatment for other lysosomal storage diseases. The
first mucopolysaccharidosis treated with ERT was MPS I
(Biomarin Pharmaceutical Inc), with ERT being subse-
quently approved for MPS VI (Biomarin Pharmaceutical
Inc) and for MPS II (Shire HGT).
MPS I
ERT for MPS I is performed by intravenous adminis-
tration of laronidase, a protein analogous to human
-iduronidase produced by genetic engineering in a Chi-
nese hamster ovary (CHO) cell expression system (Krivit,
2004).ERTwithlaronidasewasapprovedforthetreatment
ofpatientsintheUnitedStatesin2003(FoodandDrugAd-
ministration – FDA), in Europe in 2003 (European Medi-
594 Giugliani et al.cines Agency – EMEA), and in Brazil in 2005 (National
Health Surveillance Agency – ANVISA).
Preclinical studies
Studies using the canine model of MPS I showed that
intravenous administration of -L-iduronidase exhibits so-
matic distribution and is able to reduce lysosomal accumu-
lation in various tissues, with a decrease in liver GAG
accumulation and in urinary GAG excretion after two
weeks (Kakkis, 2002).
Clinical studies
Phase I/II - Ten patients ranging in age from five to
22 years received 0.58 mg/kg of -L-iduronidase intrave-
nously once a week for 52 weeks (Kakkis et al., 2001a).
Summary of the main study findings: (a) Hepato-
megaly decreased significantly in all patients and liver size
normalized in eight of the 10 patients as early as in the 26
th
week; (b) The height and weight growth rate increased by
anaverageof85%and131%,respectively,inthe52
ndweek
in six prepubescent patients; (c) The mean maximum mo-
tion range of shoulder flexion and elbow extension in-
creased significantly; (d) The number of sleep apnea and
hypopnea episodes decreased by 61%; (e) Heart function
(evaluated by The New York Heart Association functional
classification) improved by one or two classes in all pa-
tients; (f) Urinary GAG excretion decreased after three or
four weeks of treatment; (g) Serum anti--L-iduronidase
antibodies were detected in four patients.
Phase II/III - A randomized, double-blind, placebo-
controlled, multinational study was performed, including
45 patients with MPS I (one with Hurler, 37 with Hurler-
Scheie, and seven with Scheie), randomized to receive
0.58 mg/kg of either laronidase or placebo intravenously
once a week for 26 weeks (Wraith et al., 2004).
Summary of the main study findings: (a) After
26weeksoftreatment,thepatientswhoreceivedlaronidase
showed a mean improvement of 5.6 percentage points in
thepredictednormalForcedVitalCapacity(FVC)(median
3.0; p = 0.009) and 38.1 meters of distance in the Six-
Minute Walking Test (6MWT) (median 38.5; p = 0.066;
p=0.039,analysisofcovariance);(b)Theuseoflaronidase
also significantly reduced hepatomegaly and urinary GAG
excretion; (c) In the more severely affected patients there
wasimprovementinapnea/hypopneaandshoulderflexion;
(d) Laronidase was well tolerated and practically all pa-
tientsreceivingtheenzymedevelopedIgGantibodies,with
no apparent clinical effect.
Phase IV - A prospective, open-label, multinational
study that included 20 children (16 with Hurler syndrome
andfourwithHurler-Scheiesyndrome),allunderfiveyears
of age. All patients received intravenous treatment with
0.58 mg/kg or 1.16 mg/kg laronidase weekly for 52 weeks
(Wraith et al., 2007).
Summaryofthemainstudyfindings:(a)Toleranceto
laronidasewasgoodwithbothdosages;(b)GAGlevelsde-
creased by approximately 50% in the 13
th week of treat-
ment and 61.3% in the 52
nd week; (c) The liver edge
decreased by 69.5% on palpation in those patients with a
palpable liver at the time the study started; (d) The propor-
tion of patients with left ventricular hypertrophy decreased
from53%to17%inthe52
ndweek;(e)Aglobalassessment
of the sleep studies revealed improvement or stabilization
in 67% of the patients; (f) The apnea/hypopnea index de-
creased by 5.8 events per hour.
MPS II
ERT for the treatment of MPS II is performed by in-
travenousadministrationofidursulfase,aglycosylatedpro-
tein analogous to native human iduronate-2-sulfatase,
produced by genetic engineering in a continuous human
cell line (Muenzer et al., 2007). ERT with idursulfase was
approved for the treatment of patients in the United States
in July 2006 (FDA), and in Europe in January 2007
(EMEA). In Brazil, registration with ANVISA occurred in
2008.
Preclinical studies
The animal model used for MPS II was a mouse
(IdS-KO) whose IDS gene had been modified by genetic
engineering techniques. The study performed by Muenzer
etal.(2002)demonstratedthatIdS-KOmicealreadyexhib-
ited increased urinary GAG excretion at six weeks of age,
and at 10 weeks of age they showed evidence of skeletal
and facial abnormalities. GAG accumulation in the liver,
kidneys, lungs, and heart valves was evident at all ages.
Weekly doses of idursulfase (0.5 mg/kg) reduced urinary
GAG excretion in these mice after the third infusion. The
reductioninGAGintheliver,kidneys,heart,spleen,lungs,
skin, and skeletal musculature was more pronounced in the
animals treated with the 1 mg/kg dose. Another study (Gar-
cia et al., 2007) indicated that doses given weekly or every
two weeks reduced urinary GAG excretion and hepato-
megaly in the animals tested. These studies demonstrated
thatidursulfasewaseffectiveinreducingthelevelofGAGs
in urine and tissue in mice.
Clinical studies
PhaseI/II-Adouble-blindstudythatincluded12pa-
tients aged 5 years or older, divided into three treatment
groups. The groups received infusions of idursulfase every
two weeks, at the following doses: 0.15, 0.50, and
1.50 mg/kg. The study duration was 27 weeks (Muenzer et
al., 2007).
Summary of the main study findings: (a) All patients
treated with idursulfase, regardless of the dose, showed a
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first infusion, with a faster decrease in the groups receiving
the 0.5 and 1.5 mg/kg doses; (b) A reduction in liver and
spleen volume occurred; (c) A significant increase in walk
test distance (p = 0.013) was observed in the groups that re-
ceived 0.50 and 1.50 mg/kg of idursulfase; (d) One year of
treatment with idursulfase was well tolerated; (e) IgG anti-
bodies were detected in 6/12 patients (three in the group
that received 0.5 mg/kg and three in the group that received
1.5 mg/kg). The development of antibodies did not have
any clinical or biological impact on idursulfase activity.
None of the patients developed anti-idursulfase IgE anti-
bodies.
PhaseII/III-Aninternational,multicenterstudythat
included 96 patients ranging from five to 31 years of age,
divided into three groups: placebo, idursulfase (0.5 mg/kg)
once a week, and idursulfase (0.5 mg/kg) every two weeks.
The duration of the study was 53 weeks. Randomization
was stratified by age and by disease score at baseline
(6MWT and FVC%) (Muenzer et al., 2006).
Summary of the main study findings: (a) The com-
bined variable (FVC% and 6MWT) score was significantly
higher in the groups that received idursulfase; (b) After
53 weeks of weekly idursulfase infusions, the 6MWT dis-
tance increased significantly; (c) The predicted FVC in-
creased in patients who received idursulfase weekly; (d)
With respect to absolute FVC, there was a significant in-
crease in the weekly idursulfase group; (e) Liver volume
decreased by more than 20% after 18 weeks of treatment in
both groups that received idursulfase; (f) About 80% of pa-
tients with hepatomegaly exhibited normal liver volume at
between 18 and 53 weeks of treatment; (g) After 18 weeks
of treatment, spleen volume decreased by approximately
20% to 25% in the groups that received idursulfase weekly
and every other week, respectively; (h) After 53 weeks,
spleen volume remained significantly reduced in the
groupstreatedwithidursulfase;(i)Atweek53,GAGlevels
in the idursulfase groups were significantly lower. After
53 weeks of treatment, regardless of the idursulfase dosing
regimen, 26/64 patients (40.6%) exhibited normal urine
GAG levels, and the majority of patients were close to nor-
mal limits; (j) An improvement in elbow joint mobility was
observed; (k) One year of treatment with idursulfase was
well tolerated; (l) IgG antibodies were detected in 15 pa-
tients in the group that received idursulfase weekly and in
15 patients of the group that received idursulfase every two
weeks; (m) IgM antibodies occurred in two patients, one in
each idursulfase treatment group; (n) There was no impact
on the central nervous system.
MPS VI
ERT for the treatment of MPS VI is performed by in-
travenous administration of galsulfase, a recombinant form
of the enzyme N-acetylgalactosamine 4-sulfatase,
synthesized by means of genetic engineering from Chinese
hamsterovarycells(Fulleretal.,1998;Auclairetal.,2003;
Harmatz et al., 2008). The marketing and use of galsulfase
was approved in the United States in 2005 (FDA), in the
European Union in January 2006 (EMEA), and was regis-
tered with ANVISA in February 2009.
Preclinical studies
Studies using an experimental model of MPS VI
(cats) showed that administration of galsulfase produced a
significant improvement in some signs of the disease (Bie-
lickietal.,1999;Turneretal.,1999;Kakkis,2002;Auclair
et al., 2003). They also showed a decrease in GAG storage
in organs, an increase in joint mobility, and prevention or
slowed progression of skeletal disease.
Clinical studies
Phase I/II - The study by Harmatz et al. (2005b) was
performed in six patients, using two different doses of the
drug, 1 mg/kg and 0.2 mg/kg, given in weekly infusions
during 48 weeks.
Summary of the main study findings: (a) The drug
was well tolerated; (b) There was a reduction in GAG ex-
cretion via the urine.
Phase II - The study, performed in 10 patients, used
the 1 mg/kg dose established in the previous study for 48
weeks, with weekly intravenous infusions (Harmatz et al.,
2005a).
Summary of the main study findings: (a) Confirma-
tion of the results of the phase I/II study; (b) Improvement
in the ability to climb stairs; (c) Improvement in the 12-mi-
nutewalktest;(d)Feelingofimprovementinjointstiffness
and pain.
Phase III - The study used the same dose and admin-
istration method as the phase II study, but now with 39 pa-
tients for 24 weeks (Harmatz et al., 2006).
Summary of the main study findings: (a) Confirma-
tionoftheresultsofthepreviousstudy;(b)Improvementin
general resistance measured by means of the 12-minute
walk test, and in the ability to climb stairs; (c) Reduction in
urine GAG excretion; (d) Of the 54 patients who partici-
pated in these studies, only one did not develop specific an-
tibodies to galsulfase.
Guidelines For Enzyme Replacement Therapy
MPS I
The laronidase prescribing information approved by
FDA(NDC58468-70070-1)andEMEAin2003,andregis-
tered in Brazil (ANVISA) in 2005, states that laronidase is
indicated for patients with the Hurler and Hurler-Scheie
forms of mucopolysaccharidosis type I and for patients
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toms. In Latin America, the only country that has currently
published a consensus on the diagnosis and treatment of
MPS I is Argentina (Argentine Pediatrics Society, 2008).
The inability of intravenously administered laroni-
dase to reach the central nervous system, at least at the cur-
rently recommended dose of 0.58 mg/kg per week, limits
its effects on neurological impairment in patients with the
severe and neurodegenerative form of the disease (Hurler
phenotype), therefore being indicated for the treatment of
non-neurological symptoms of the disease.
The use of ERT in association with HSCT has not yet
been established, although there is evidence that this com-
binationreducespulmonarycomplicationsfollowingtrans-
plant (Tolar et al., 2008). To date, the primary justification
for defending the use of ERT in patients in whom HSCT is
indicated is to improve the patient’s physical condition
while a compatible donor is sought (Wraith, 2001).
Objectively, ERT should be indicated in the follow-
ing cases in which there is a confirmed diagnosis of MPS I:
Patientsofanyagewhoaresymptomaticandwhoexhibitat
least one clinical manifestation that responds to treatment
with ERT. These manifestations may be: (a) Respiratory
diseases, such as upper airway obstructions, recurrent in-
fection, restrictive diseases; (b) Cardiac disorders, such as
cardiomyopathy and valve disease; (c) Osteoarticular dis-
orders that impair locomotion or make it difficult, causing
the patient to be dependent on other people for carrying out
every-day activities; (d) Sleep apnea with an apnea index
(AI) higher than one event/h of sleep for patients under
17 years of age, and higher than 5 events/h of sleep for
adults; (e) Mean nocturnal O2 saturation < 92% in children
and<85%inadults;(f)Patientswhicharehardtointubate.
Drug characteristics and Usage Regimen (dose, fre-
quency, and infusion time) for MPS I are presented in
Table 1.
A recent study (Giugliani et al., 2009) indicated that
the administration of a double dose every other week does
not result in significant disadvantages to the patient, and
this administration regimen may be considered in cases in
which a weekly infusion regimen is difficult to implement
for some operational or logistical reason.
MPS II
ERT can be performed in all symptomatic patients
with a confirmed MPS II diagnosis. Although Wraith et al.
(2008) suggested that patients with significant CNS in-
volvement should receive ERT for 12 to 18 months, and
maintenance of ERT should be assessed after this period,
the overall benefits of this treatment are questionable in pa-
tients with severe impairment of cognitive functions, since
the intravenously administered enzyme does not cross the
blood-brain barrier.
Objectively, ERT should be indicated in the follow-
ing cases with a confirmed diagnosis of MPS II: Patients of
anyagewhoaresymptomatic,whodonothaveseverecog-
nitive impairment, and who exhibit at least one clinical
manifestation that responds to treatment with ERT: (a) Re-
spiratory diseases, such as upper airway obstructions, re-
current infections, restrictive diseases; (b) Osteoarticular
disorders that impair locomotion or make it difficult, caus-
ing the patient to be dependent on other people for carrying
out every-day activities; (c) Sleep apnea frequency higher
than one event/h for patients under 18 years of age, and
higher than 5 events/h for adults; (d) Mean nocturnal O2
saturation < 92% in children and < 85% in adults.
Although ERT has not been tested in clinical trials
with patients under the age of 5 years, it has been used in
small children in isolated cases, with no indications that the
safety and efficacy profile are different from those ob-
served in older children.
Drug characteristics and Usage Regimen (dose, fre-
quency, and infusion time) for MPS II are presented in Ta-
ble 1.
MPS VI
ERTmaybeadministeredtoallsymptomaticpatients
with a confirmed diagnosis of MPS VI, and is recom-
mended as treatment of choice for this condition. Studies
have demonstrated improvement in the walking test and in
theabilitytoclimbstairs(Harmatzetal.,2006;Giuglianiet
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Table 1 - Characteristics of the Drug and Usage Regimen (dose, frequency, and infusion time) for MPS I., MPS II and MPS VI.
Mucopolysaccharidosis I Mucopolysaccharidosis II Mucopolysaccharidosis VI
Drug and manufacturer Aldurazyme® (Genzyme Corporation) Elaprase® (Shire HGT) Naglazyme® (BioMarin Pharmaceuti-
cals)
How supplied Vials containing 2.9 mg/5 mL
(0.58 mg/mL)
Vials containing 6 mg/3 mL
(2 mg/mL)
Vials containing 5 mg/5 mL
(1 mg/mL)
Standard dose and route of
administration
0.58 mg/kg, intravenously 0.50 mg/kg, intravenously 1 mg/kg, intravenously
Frequency Weekly (7  3 days) Weekly (7  3 days) Weekly (7  3 days)
Infusion time Approximately 3-4 h From 1 to 3 h A minimum of 4 hal., 2007), improvement in MPS VI-related bone disease,
as well as improvement in growth pattern in a patient
treated as of the eighth week of life (McGill et al., 2009). It
is known, however, that some tissues, such as the cornea,
due to their reduced perfusion, and the central nervous sys-
tem, due to the blood-brain barrier, are not significantly af-
fected by the action of the intravenously administered
enzyme (Giugliani et al., 2007; Clarke, 2008).
Objectively, ERT should be indicated in the follow-
ing cases with a confirmed diagnosis of MPS VI: Patients
ofanyagewhoaresymptomaticandhaveatleastoneclini-
cal manifestation that responds to treatment with ERT.
These manifestations may be: (a) Respiratory diseases,
such as upper airway obstructions, recurrent infections, re-
strictive diseases; (b) Osteoarticular disorders that impair
locomotionormakeitdifficult,causingthepatienttobede-
pendent on other people for carrying out every-day activi-
ties; (c) Sleep apnea frequency higher than 1 event/h for
patients under 18 years of age, and higher than 5 events/h
for adults; (d) Mean nocturnal O2 saturation < 92% in chil-
dren and < 85% in adults; (e) Patients who are hard to
intubate.
Drug characteristics and Usage Regimen (dose, fre-
quency,andinfusiontime)forMPSVIarepresentedinTa-
ble 1.
Other Information Common To The Handling,
Preparation, and Administration of Laronidase,
Idursulfase, and Galsulfase
Usage Regimen - (a) Use of the standard dose is rec-
ommended. Some small adjustments may be made, as long
as the dose used does not vary more than 10% in relation to
the standard dose. Similarly, the final monthly dose should
not vary more than 10% with regard to the ideal monthly
dose, established according to the standard dose. (b) Dose
calculation should be reviewed every three months, whe-
ther the patients are children or adults. (c) It is recom-
mended that the infusion be initially administered in a
hospital environment and preferably in a bright environ-
ment that is pleasant for the patient. Given the increasing
number of patients throughout the country who are receiv-
ing ERT, it is recommended that this procedure be stan-
dardized within the Brazilian Integrated Health System
(SUS), so as to become one of the procedures officially
consideredtobeperformedina“dayhospital”setting.(d)It
is important to alternate the peripheral vein puncture sites.
Whenever a totally implanted central catheter is used, use
of EMLA® is recommended (1 h or1h3 0m i npre-punc-
ture). (e) The patient should be observed for at least1ha f -
ter the end of the infusion, at least during the first three
months of treatment, if it is not possible to do so for the
idealperiod,whichissixmonths.Afterthisobservationpe-
riod, if there is no complicating factor, the patient may be
released immediately following the infusion.
Contraindications - ERT is not indicated for women
who are pregnant or nursing, unless it is absolutely essen-
tial. Terminal patients should not receive ERT either, nor
should patients with a severe concomitant disease, the
prognosis of which will not change as a result of the ERT.
Premedication - Possible infusion reactions are very
specific to each patient, so the physician should assess the
need for premedication and its strength on a case-by-case
basis. Premedication with antipyretics and/or antihista-
minesisgenerallyusedforERTinpatientswithMPSI.For
patients with MPS VI receiving ERT, antihistamines have
been used, with or without antipyretics, about 1 h prior to
the start of the infusion. If there is an infusion reaction that
persists even with the use of antipyretics and antihista-
mines, the use of corticosteroids prior to ERT should be
considered, e.g., prednisolone (1 mg/kg), 12 h and1hb e -
fore the infusion. The use of premedication is not routinely
prescribed in MPS II patients receiving ERT, except for
preventing recurrence of infusion reactions.
Drug Preparation - Using proper asepsis techni-
ques,thedrugshouldbepreparedasfollows:(a)Determine
the number of vials to be diluted, based on the patient’s
weight and the standard recommended dose of the replace-
mentenzyme,adjustingitinsuchawaythatwholevialsare
used; (b) Remove the vials from the refrigerator, to allow
them to reach room temperature. These vials should not be
heated;(c)Thesolutionistransparentorsomewhatyellow-
ish, and clear or slightly opalescent, as some transparent
particlesmaybepresent.Ifthesecharacteristicsofthesolu-
tion are altered, these vials should not be used; (d) Deter-
minethetotalfinalvolumetobeinfused,whichdependson
the patient’s weight and the drug to be prepared: MPS I:
100 mL (weight  20 kg) or 250 mL (weight > 20 kg); MPS
II:100mL(forallweights)plusthetotalcalculatedvolume
of idursulfase; MPS VI: 250 mL (in general – for weights
less than or equal to 20 kg; in patients who are susceptible
to volume overload, the physician may consider the total
volume of 100 mL); (e) Slowly aspirate the calculated vol-
ume of enzyme from the vials, taking care not to shake the
solution, since shaking can denature the product and render
it biologically inactive; (f) From the corresponding bag of
physiological saline solution (100 mL or 250 mL), remove
a volume equal to that calculated and aspirated from the vi-
als of enzyme, so that, after adding the volume of enzyme,
thetotalfinalvolumeof100mLor250mL,isreconstituted
(this step is not necessary for idursulfase, since the orienta-
tion in the prescribing information is to dilute the total cal-
culated volume of idursulfase in 100 mL of 0.9% Sodium
Chloride Injection); (g) The addition of the enzyme solu-
tion to the bag of physiological saline solution has to be
slow, and the bag containing the final solution has to be ro-
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drug; (h) This solution should be used immediately. If im-
mediate use is not possible, the solution must be stored un-
der refrigeration (2 °C to 8 °C) for a maximum period of
36hfrompreparationtotheendofadministrationoftheso-
lution(24hforidursulfase,accordingtotheBrazilianprod-
uct information). Do not leave the prepared solution at
room temperature; (i) In the case of MPS I, the use of albu-
min is recommended in the United States, but it is not used
in the European countries. In Brazil, the ANVISA-
approvedprescribinginformationalsorecommendsitsuse.
However, the experience of Brazilian specialists indicates
that the use of albumin can be dispensed with.
Infusion Rate - After preparation of the drug, the in-
fusion should be administered in an incrementally increas-
ing manner as recommended below. However, in the event
of reactions associated with the infusion, these incremen-
tally increased rates and the final maximum rate reached
may be modified according to each patient’s tolerance.
MPS I: (a) Weight less than or equal to 20 kg (total
volume 100 mL): 2 mL/h x 15 min; 4 mL/h x 15 min;
8 mL/h x 15 min; 16 mL/h x 15 min; 32 mL/h x ~3 h; (b)
Weight more than 20 kg (total volume 250 mL): 5 mL/h x
15 min; 10 mL/h x 15 min; 20 mL/h x 15 min; 40 mL/h x
15 min; 100 mL/h x ~3 h.
MPSII:8mL/hx15min;16mL/hx15min;24mL/h
x 15 min; 32 mL/h x 15 min; 40 mL/h x ~2 h. This rate may
be increased by 8 mL/h x 15 min, without exceeding the
maximum rate of 100 mL/h.
M P SV I :6m L / hx1h ;8 0m L / hx~ 3h .
Use of Filters - It is recommended that the adminis-
trationoflaronidase,idursulfase,andgalsulfasesolutionbe
performed using an infusion set with a 0.2 m filter.
Adverse Reactions – Conduct - The infusion reac-
tions most commonly reported with the use of ERT were:
pyrexia,headache,abdominalpain,dyspnea,chills,arthral-
gia, pruritus, hypertension/hypotension, urticaria, and
exanthema (rash). If an infusion reaction occurs, regardless
of whether premedication was used, the following mea-
sures should be taken, in this order, until the symptoms
improve: reduction of the infusion rate, temporary discon-
tinuation of the infusion, additional administration of anti-
pyretics and antihistamines.
If a severe hypersensitivity reaction or an anaphyl-
acticreactionoccurs,theinfusionshouldbestoppedimme-
diately and appropriate supportive measures should be
promptly taken, according to the picture presented. The use
of corticosteroids and airway and venous access mainte-
nance measures may be necessary, and resuscitation mea-
sures must be implemented in extreme cases. For this
reason, it is recommended that the infusion center should
have the equipment necessary for comprehensive care of
cardiorespiratory arrest (crash cart) and have easy access to
the emergency room.
If the use of epinephrine is considered, it should be
used with extreme caution, due to the increased prevalence
of coronary disease in many patients with MPS.
The risk-to-benefit ratio of enzyme administration
following a severe hypersensitivity reaction or anaphyl-
acticreactionshouldbeevaluatedand,ifERTinfusionsare
reinitiated, appropriate resuscitation measures should be
available for use in extreme cases.
Ideally, before initiation of ERT, blood should be
drawn for antibody level determination. This sample shall
be kept until this determination is necessary, i.e., in the
eventthepatientexperiencesaninfusionreaction.Ifthepa-
tient does experience an infusion reaction, blood should be
drawn again between 1 and 2 h from the onset of the reac-
tion,oraccordingtotheenzymemanufacturer’sdirections.
Adverse Reactions – Pharmacovigilance - Any
side-effect should be reported as soon as possible to the
Pharmacovigilance Department of ANVISA and to the
pharmacovigilance section of the hospital, if applicable. In
addition, the companies responsible for the drugs laro-
nidase(Genzyme),idursulfase(Shire/HGT),andgalsulfase
(BioMarin) request that they be notified via their medical
departments, for pharmacovigilance purposes.
ClinicalRoutine-Beforethestartofeachinfusion,a
briefhistoryshouldbetakenandatargetedphysicalexami-
nation, including the checking of vital signs, should be per-
formed.Thecollectionofsamplesformonitoringtestsmay
be indicated. Patients do not need to be fasting nor have
their diets modified because of the infusion.
Criteria for Discontinuation of Treatment - To
date, there are no established criteria determining the indi-
cation for discontinuation of treatment, however it is rec-
ommended that ERT be discontinued: (a) During
pregnancy and breastfeeding; (b) In patients who, despite
ERT, have progressed to terminal disease or experience a
significant worsening of their clinical parameters, mea-
sured at least every six months and preferably over a period
of at least 12 months of ERT; (c) In patients who do not ex-
hibit any measurable clinical benefit, taking into consider-
ationthenaturalrateofprogressionofthedisease,basedon
parameters measured at least every six months and prefera-
bly over a period of at least than 12 months of ERT.
Thepossibilityofdiscontinuationoftreatmentshould
bementionedtotheparents/patientorlegalguardianswhen
ERT is being considered and prior to its initiation. During
clinical monitoring of a patient receiving ERT, the ERT
therapeutic response parameters should be evaluated peri-
odically and discussed with the parents/patient or legal
guardians. If discontinuation of ERT is being considered,
this should be discussed with the parents/patient or legal
guardians.
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shouldbetakenintoaccountthatthefewreportsonERTin-
terruption found in the literature show that discontinuation
of this treatment can lead to a rapid deterioration of the pa-
tient’s clinical picture (Anbu et al., 2006; Wegrzyn et al.,
2007).
Presymptomatic Treatment - Although there are
fairly encouraging results, the benefits of presymptomatic
treatment observed in various case reports have not yet
been assessed via clinical trials (which are currently under
way in the case of MPS VI). Thus, in cases in which the
physicianconsidersittobeindicated,thetreatmentofMPS
I, MPS II, and MPS VI prior to the onset of symptoms
shouldbepresentedtothefamilyasanexperimentalproce-
dure,anditissuggestedthatanInformedConsentFormap-
proved by the competent ethical bodies be utilized.
Treatment in Children Under Five Years of Age -
Theuseoflaronidaseinchildrenunderfiveyearsofagehas
beenshowntobesafe,asdemonstratedinaspecificclinical
study in small children with MPS I (Wraith et al., 2007).
This favorable result in terms of safety has also been con-
sistently observed in several cases of young MPS II and
MPS VI patients treated with ERT (Kim et al., 2008), al-
though it has not yet been formally assessed in small chil-
dren via clinical trials.
Alternative Routes of Administration - Brazil was
a pioneer in the intrathecal administration of recombinant
enzymeinapatientwithMPSI,fortreatmentofspinalcord
compression. This experience had encouraging results and
was reported in the literature (Muñoz-Rojas et al., 2008).
Additional cases of Brazilian patients with MPS and spinal
cord compression (one with MPS I and another with MPS
VI) were similarly treated and the reports are being pre-
pared for publication. However, intrathecal administration
oftheenzymeshouldbeconsideredanexperimentalproce-
dure for the time being.
Home Infusion - Home infusion may constitute an
optionforpatientswho,afterthreetosixmonthsofhospital
infusion, have not experienced any significant infusion re-
actions. It is recommended that both the infusion location
and the drug storage and preparation location be approved
by the person in charge of the reference center’s medical
staff, and that a professional nurse trained for this specific
procedure monitor the infusion all the time and regularly
inform the reference center about the procedure. The pa-
tient undergoing home infusion must have regular medical
checkups at the reference center at least every three months
(Cox-Brikman et al., 2007).
Prospects and Conclusions
The authors of this study are convinced that a better
future for patients suffering from mucopolysaccharidoses
depends on the proper identification, understanding and
management of the multisystemic manifestations of these
diseases, including supportive measures (which should be
part of the regular multidisciplinary care of these patients)
and specific therapies. There are indications that earlier de-
tection and treatment of patients, possibly by means of
newborn screening, may contribute to a better prognosis. A
definitive cure may perhaps be achieved through gene ther-
apy, but this moment could still take some time to arrive.
Although inhibition of glycosaminoglycan synthesis
andtherestorationofenzymeactivitywithsmallmolecules
may also come to play a role in the management of MPS,
the main advance currently available is ERT. Along with
HSCT (for specific situations), ERT has enabled a radical
change in the panorama of treatment for mucopoly-
saccharidosis I, II, and VI in the past decade and is helping
to provide a better understanding of the physiopathology of
the disease (Pereira et al., 2008) and potential biomarkers
(Randall et al., 2008). It is further possible that its benefits
may be extended to MPS IV A shortly, with prospects for
the treatment of MPS III A and of the cognitive deficit in
MPS II via administration of the enzyme directly into the
central nervous system (CNS).
Presently,alargenumberofBraziliancenters,includ-
ing departments in all regions of the country, have already
some experience with ERT for MPS I, II, and VI, acquired
not only by treating patients, but also through the participa-
tion of some groups in clinical trials involving ERT for
these conditions. Taking the three types of MPS together,
over 200 patients have been treated with ERT in our coun-
try so far. The experience of professionals, along with the
data available in the international literature, enabled the
drafting of this document, produced with the purpose of
joining and harmonizing the information available on the
treatment of these severe and progressive diseases, which
are, fortunately, treatable today, offering new prospects for
Brazilian patients affected by these conditions.
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